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The RASSF1A isoform of RASSF1 is frequently inactivated by epigenetic alterations in human cancers, but
it remains unclear if and how it acts as a tumor suppressor. RASSF1A overexpression reduces in vitro colony
formation and the tumorigenicity of cancer cell lines in vivo. Conversely, RASSF1A knockdown causes multiple
mitotic defects that may promote genomic instability. Here, we have used a genetic approach to address the
function of RASSF1A as a tumor suppressor in vivo by targeted deletion of Rassf1A in the mouse. Rassf1A null
mice were viable and fertile and displayed no pathological abnormalities. Rassf1A null embryonic fibroblasts
displayed an increased sensitivity to microtubule depolymerizing agents. No overtly altered cell cycle param-
eters or aberrations in centrosome number were detected in Rassf1A null fibroblasts. Rassf1A null fibroblasts
did not show increased sensitivity to microtubule poisons or DNA-damaging agents and showed no evidence of
gross genomic instability, suggesting that cellular responses to genotoxins were unaffected. Rassf1A null mice
showed an increased incidence of spontaneous tumorigenesis and decreased survival rate compared with
wild-type mice. Irradiated Rassf1A null mice also showed increased tumor susceptibility, particularly to tumors
associated with the gastrointestinal tract, compared with wild-type mice. Thus, our results demonstrate that
Rassf1A acts as a tumor suppressor gene.
Loss of heterozygosity (LOH) at chromosome 3p21.3 is ex-
tremely common in human carcinomas of the lung and breast
(14) and is believed to be a critical early event in the patho-
genesis of lung cancer (11, 42). Comparative analysis of dele-
tions in this region in lung and breast cancer cell lines has
identified a critical deletion interval of 120 kb containing eight
genes (14). While none of the genes in this deletion region are
mutated at a significant frequency in cancer (14), one of these
genes, RASSF1, is a strong candidate as the major tumor sup-
pressor gene on the basis of its frequent epigenetic silencing
and LOH in lung cancers (6).
The two major isoforms of RASSF1, A and C, are produced
by alternative promoter usage and mRNA splicing (2, 6). Tran-
scripts from both isoforms share four common exons (exons 3
to 6), which encode a Ras association (RA) domain, PEST
sequences, and a consensus phosphorylation site for ataxia
telangiectasia-mutated (ATM) kinase (6). Since the RASSF1
RA domain can associate with Ras oncoproteins in vitro (21)
and ATM kinases play an essential role in DNA damage,
RASSF1A/C may serve as a link between these two signaling
pathways. Overexpression and knockdown studies of RASSF1
have implicated RASSF1A in regulating cell cycle progression
and RASSF1C in Ras-mediated cellular activities. Both iso-
forms localize to the microtubules and the mitotic spindle,
suggesting a possible involvement in regulating microtubule
dynamics (39). Microtubules are protected against nocodazole-
induced depolymerization by RASSF1A, and to some extent by
RASSF1C, overexpression (39). The RASSF1 isoforms have
been reported to play a role in mitotic progression; overex-
pression of RASSF1A but not RASSF1C causes a promet-
aphase arrest by preventing activation of the anaphase-pro-
moting complex/cyclosome (APC/C), whereas short interfering
RNA-mediated depletion of RASSF1A accelerates mitotic
progression and causes mitotic defects (33). Furthermore,
overexpression of RASSF1A has been shown in numerous
studies to result in reduction of in vitro colony formation and
anchorage-independent growth and reduction of the tumori-
genicity of cancer cell lines in vivo (2, 6, 9). In contrast, only
one study has reported that overexpression of RASSF1C re-
sulted in growth inhibition in vitro and in vivo, and then only in
the prostate and renal cell carcinoma cell lines LNCaP and
KRC/Y, respectively, not the lung cancer line U2020 (15).
These results suggest that RASSF1A function is distinct from
RASSF1C and that RASSF1A may function as a tumor sup-
pressor gene. Indeed, epigenetic inactivation of RASSF1A is
frequently reported in human cancers (reviewed in reference
7) and in some cases has been shown to correlate with poor
prognosis (17, 41, 43). In contrast, only one study has reported
loss of expression of RASSF1C in cancer (38).
Here, we have generated Rassf1A null and conditional mice
in order to dissect the functions attributed to the RASSF1
isoforms. We reexamine the role of RASSF1A in protecting
microtubule stability and cell cycle progression and specifically
examine the role of RASSF1A as a tumor suppressor gene.
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MATERIALS AND METHODS
Construction of the Rassf1A targeting vector and generation of Rassf1A mu-
tant mice. To generate the Rassf1A targeting vector (pAH19), DNA fragments
for the 5, conditional, and 3 homology arms were amplified from AB2.2
genomic DNA by PCR using Platinum PCR Supermix High Fidelity (Invitrogen,
San Diego, CA) for 10 to 18 cycles. The homology arms consisted of a 4.5-kb 5
arm (containing the entire BLU gene [GenBank accession number AF333027]
flanked by AscI sites), a 1.7-kb conditional arm (containing exon 1 flanked by
HindIII sites), and a 4.4-kb 3 homology arm (containing exons 1, 2, and 2
flanked by NotI sites), which were cloned into pGEM T-Easy (Promega, Mad-
ison, WI), sequenced, and then subcloned into the AscI, HindIII, and NotI sites
of pFlexible (36), respectively. Ten micrograms of the PvuI-linearized pAH19
was electroporated into 107 AB2.2 embryonic stem (ES) cells (from mouse strain
129S5/SvEvBrd) (24) and grown under 3-g/ml puromycin selection. Cells were
cultured on a lethally irradiated SNL76/7 feeder layer (18). ES clones were
picked into 96-well plates after 9 days of drug selection and expanded, and
targeted clones were identified by Southern blot analysis using PCR-amplified
probes on NdeI- or SacII-digested genomic DNA with a 5 or 3 external probe,
respectively. pAS3 is the 254-bp 5 external probe (forward primer, 5-TCT GGA
GGG TGA GAC TCG GTT TTG TAA A-3; reverse primer, 5-TAC ATA
GTG AGA CTT TGT CTC AGA AAA ATC AAC CTC CTT C-3), and pAT1
is the 579-bp 3 external probe (forward primer, 5-GCT GAG ACT GAG CAG
AAA ATC AAG GAC TAC AAT GG-3, and reverse primer, 5-CTT GGC
CAT GCC GTT CAG TTC GCT CAA AGA GTG C-3). The correctly targeted
allele was termed Rassf1ABrdm1 (m1). To generate null and conditional alleles, a
cell line with the m1 allele was electroporated with 10 g of a Cre-expressing
plasmid (pTURBO-Cre; GenBank accession number AF334827) or an Flpe-
expressing plasmid (pFLPe) (27), respectively. After 3 days of culture, the cells
were trypsinized, reseeded at 3  105 cells/10-cm-diameter plate, and cultured in
0.2 M 2-deoxy-2-fluoro--D-arabinofuranosyl-5-iodouracil (FIAU) for 5 days.
After this time, the cells were grown for a further 3 days in drug-free medium
before the resulting colonies were trypsinized, pooled, and analyzed by Southern
blotting using the pAS3 probe on KpnI-digested genomic DNA or using the
pR20P probe (a 1.2-kb PstI fragment from the conditional arm) on HindIII-
digested genomic DNA. The allele in the Flp-transfected clones showing loss of
the 12.1-kb KpnI fragment but not the 1.7-kb HindIII fragment was termed
Rassf1ABrdc1 (c1) (“conditional” allele). The allele generated with Cre, which
showed a 9.1-kb KpnI fragment and loss of the 1.7-kb HindIII fragment, was
termed Rassf1ABrdm2 (m2) (“null” allele). ES cell clones for the null and condi-
tional alleles were transmitted through the germ line and bred to homozygosity
(maintained on a mixed 129/Sv-C57BL/6 background). Mice were housed in
accordance with Home Office regulations (United Kingdom). For tumor induc-
tion studies mice were whole body irradiated with a sublethal dose of 3.5 Gy at
4 weeks of age.
Genotyping of Rassf1A mutant mice by genomic PCR. Genomic DNA was
amplified in 50-l reaction mixtures using 45 l Platinum PCR Supermix (In-
vitrogen) and 100 ng of each primer pair (RSF-5/RSF-3 or RSF-C/RSF-3). The
primers were as follows: RSF-3 (reverse primer), 5-CCA GGC TTC CTT CTC
ACT CCT CTG CCG C-3; RSF-5 (forward primer), 5-CTC GCC CCT GTC
AGA CCT CAA TTT CCC-3; and RSF-C (forward primer), 5-AAG GAG
AAA GAA AGC TGC TCT GGG GTT CT-3. The PCR cycle profile was as
follows: 1 cycle at 94°C for 2 min followed by 30 cycles at 94°C for 30 s, 65°C for
1 min, and 72°C for 30 s, with a final cycle of 72°C for 10 min.
Reverse transcriptase PCR (RT-PCR). RNA was extracted from /, c1/c1,
and m2/m2 mouse lung (RNAqueous; Ambion, Austin, TX), and 1.5 g of total
RNA was used to generate cDNA (RETROscript; Ambion). Specific primers
were as follows: for Rassf1A exons 1, 1, and 2 (330-bp product), 5-ATG
TCG GCG GAG CCA GAA CTC ATT GAA CTA-3 and 5-CAC GTT CGT
ATC CCG CTC TAG TGC AGA GT-3; for Rassf1C exons 2 and 3 (220-bp
product), 5-ATG GGC GAG GCT GAA ACA CCT TCC TTC GAA-3 and
5-CAG GCT CAT GAA GAG GTT GCT GTT GAT CT-3; for Rassf1 exons
3 and 4 (372-bp product), 5-GAT GAG GCT GTA GAG CGG GAG ACA
CCC G-3 and 5-CTT GGC CAT GCC GTT CAG TTC GCT CAA AG-3; and
for -actin exons 2 and 3 (215-bp product), 5-ACC AAC TGG GAC GAT ATG
GAG AAG A-3 and 5-TAC GAC CAG AGG CAT ACA GGG ACA A-3.
The cDNA was amplified in 50-l reaction mixtures using 45 l Platinum PCR
Supermix (Invitrogen) and 100 ng of each primer pair with the following PCR
cycle profile: 1 cycle at 94°C for 2 min followed by 30 cycles at 94°C for 30 s, 65°C
for 1 min, and 72°C for 30 s, with a final cycle of 72°C for 10 min. All PCR
products were cloned into pGEM T-Easy and sequenced to confirm their iden-
tity.
Quantitative RT-PCR. RNA was extracted from / and m2/m2 mouse liver
(Trizol; Invitrogen), and 5 g of total RNA was used to generate cDNA (Su-
perscript II reverse transcriptase; Invitrogen). Quantitative PCR (qPCR) was
carried out using the relative quantitation comparative CT method in separate
tubes on the ABI 7900HT sequence detection system in accordance with the
manufacturer’s instructions (ABI user bulletin no. 2; Applied Biosystems, Foster
City, CA). The target sequence was designed to exons 1 and 2 of Rassf1C
(5-AGC ACA ACC AGC AGT GGC TA-3 and 5-TTG ATT TTC TGC TCA
GTC TCA-3; 167-bp product), and the reference PCR product was designed to
exons 3 and 4 of -actin (5-GAT CTG GCA CCA CAC CTT CT-3 and 5-GGG
GTG TTG AAG GTC TCA AA-3; 138-bp product). Both PCR products were
tested to confirm the presence of a single clean product by gel electrophoresis
and melt curve analysis on the ABI 7900HT sequence detection system. A
validation experiment was carried out to confirm that the PCR efficiencies of the
two products were sufficiently similar. qPCRs were performed with the Quanti-
Tect Syber Green PCR kit (QIAGEN, Valencia, CA) in accordance with the
manufacturer’s instructions, using a 50-l PCR volume, 5 ng cDNA, and 125 ng
(2.5 ng/l) primer. Five replicates of all PCRs were carried out, and the final
quantification was determined relative to RNA from a wild-type mouse. The
PCR products after qPCR were checked by melt curve analysis and gel electro-
phoresis to confirm the presence of a single clean product. The data are repre-
sented as the mean relative quantities of Rassf1C mRNA  standard deviations
(SD) (using liver RNA samples from four mice of each genotype).
Cell cycle and CD antigen analysis of thymocytes. Thymuses and spleens were
excised from 6- to 7-week-old wild-type and Rassf1A null (m2/m2) mice and were
gently crushed through 100-m cell strainers (BD Falcon, Bedford, MA) in
phosphate-buffered saline (PBS). After centrifugation and washing with PBS/2%
fetal bovine serum, cells were divided into two groups for analysis. For analysis
of CD antigen expression, cells were stained with CD2-fluorescein isothiocyanate
(FITC), CD4-phycoerythrin (PE), CD8-FITC, and/or CD45R (B220)-FITC
(Pharmingen, Palo Alto, CA) and analyzed by flow cytometry (20,000 cells
examined per sample). For cell cycle analysis, cells (1.5  106) were fixed with
70% ethanol for 30 min at 4°C, RNase A treated (2 g/ml; Sigma, St. Louis, MO)
for 30 min at room temperature, and stained with propidium iodide (50 g/ml;
Sigma), and the DNA content was analyzed by flow cytometry. All fluorescence-
activated cell sorter (FACS) data analysis was performed using WinMDI version
2.8 software.
Micronucleus assay. Blood was collected from wild-type and Rassf1A null 6- to
7-week-old and 7-month-old mice by cardiac puncture during terminal anesthe-
sia and immediately fixed in methanol overnight at	80°C. DNA, CD71 antibody
staining, and FACS analysis were performed using MicroFlow reagents from
Litron Laboratories (Rochester, NY) as described by the manufacturer. Fifty
thousand red cells were examined from each animal. For irradiation studies, 6-
to 7-week-old mice were whole body irradiated at 0.7 Gy and blood was collected
48 h later.
Histology. Tissues from wild-type and Rassf1A null mice were collected and
fixed in 10% neutral buffered formalin. Tissue samples were processed routinely
and embedded in paraffin, sectioned at 4 m, stained with hematoxylin and
eosin, and analyzed by light microscopy.
Cell growth and proliferation of MEFs. Mouse embryonic fibroblasts (MEFs)
were derived from 13.5-day-old embryos as described previously (29). All studies
were performed on four to seven independently collected batches of MEFs,
which were cultured up to passage 7 (P7). For cell growth assays MEFs were
seeded in triplicate at a density of 3  105 cells/6-cm-diameter plate at day 0.
Cells were counted daily using a Coulter counter (Beckman Coulter, Fullerton,
CA). Data were collected from cell counts of four independent experiments.
Survival assays. Cytotoxicity was evaluated using the MTT (3-[4,5-dimethyl-
thiazol-2-yl]-2,5 diphenyl tetrazolium bromide) assay, in which 4  103 wild-type
or Rassf1A null MEFs in 200 l of complete medium were placed into each well
of a 96-well plate and 24 h later were exposed to a DNA-damaging agent (methyl
methanosulfonate [MMS], mitomycin C [MMC], hydroxyurea [HU], ionizing
radiation, or UV) or microtubule-binding agent (nocodazole, vinblastine, colchi-
cine, or taxol). Exceptions include MMS treatment, in which cells were exposed
to the drug for only 1 h, and ionizing radiation, in which cells were irradiated
prior to plating. After 5 days, viability was assessed using CellTiter reagent
(Promega), according to the manufacturer’s recommendations. A minimum of
eight wells were analyzed and averaged for each data point at each dose from
four independent experiments. Results are expressed as means  SD. All DNA-
damaging and microtubule-binding chemicals were purchased from Sigma.
Spectral karyotyping. Spectral karyotyping analysis was carried out as previ-
ously described (31) on metaphase spreads prepared from wild-type and Rassf1A
null MEFs (at P1) using the mouse SkyPaint probe mixture supplied by Applied
Spectral Imaging (Vista, CA). Spectral images were captured using a Nikon
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FIG. 1. Generation of null and conditional alleles of Rassf1A. A. (Box) Through the use of alternative promoter selection and alternative
mRNA splicing of the RASSF1 transcript, three isoforms have been described, namely, RASSF1A, RASSF1B, and RASSF1C (RASSF1A mRNAs
also come in multiple tissue-related splice forms, including heart-specific RASSF1D [AF102771] and pancreas-specific RASSF1E [AF102772]) (2).
However, the two major isoforms are the ubiquitously expressed RASSF1A and RASSF1C, as RASSF1B is hematopoietic cell specific. RASSF1A
is a six-exon gene that initiates transcription at exon 1. Thus to specifically ablate the Rassf1A isoform, LoxP (L) sites were positioned to allow
Cre-mediated excision of exon 1 and generate a null knockout (m2) allele. The puro
tk cassette, flanked by FRT (F) sites, can be excised using
Flpe to generate a conditional (c1) allele. The regions of homology used in the targeting vector (pAH19) are shown in gray. Blu is a gene which
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Eclipse E800 epifluorescence microscope equipped with an SD200 SpectraCube
system (Applied Spectral Imaging). At least 20 raw spectral image files were
acquired for each genotype using Spectral Imaging version 2.3 software (Applied
Spectral Imaging) and analyzed using SkyView version 1.6.1 software (Applied
Spectral Imaging).
Microtubule stability analysis. To evaluate microtubule stability in MEFs,
cells were seeded onto polylysine-coated coverslips (Becton Dickinson) 24 h
prior to treatment with nocodazole or colcemid for 30 min at 37°C. Coverslips
were washed twice with cold PBS and were stained with mouse monoclonal
anti--tubulin antibody at 1:200 (Molecular Probes, Eugene, OR) for 1 h at room
temperature. After washing with PBS, Alexa Fluor 568-conjugated anti-mouse
secondary antibody (Molecular Probes, Eugene, OR) was used and DNA was
counterstained with Hoechst (Sigma). At each drug concentration, 100 to 150
cells were scored for microtubule integrity. Untreated cells have an extensive
network of microtubule fibers that fills the cytoplasm. Local absence of defined
fibers was scored as partial microtubule depolymerization, and the absence of
any fibers was indicative of complete microtubule depolymerization. The micro-
graphs shown are representative of 75% of the cells in terms of microtubule
integrity at each concentration. Images were obtained with a Zeiss confocal
microscope and processed using Photoshop 7.0 (Adobe Systems, San Jose, CA).
Immunofluorescence. MEFs were grown on polylysine-coated coverslips and
pulsed with 40 M bromodeoxyuridine (BrdU) for 1 h prior to fixation in 4%
paraformaldehyde. Cells were permeabilized in 80% ethanol at 	20°C and
briefly in 0.1% Triton X-100/0.02% sodium dodecyl sulfate in PBS. Cells were
blocked in 1% bovine serum albumin and stained with anti-BrdU and nuclease
(Amersham Biosciences, Piscataway, NJ), rabbit anti-PH3 at 1:400 (Upstate
Biotechnology, Waltham, MA), or rabbit anti--tubulin 1:1,000 (Sigma). After
washing with detergent, cells were incubated with Alexa Fluor 568-conjugated
anti-mouse secondary antibody or Alexa Fluor 568-conjugated anti-rabbit sec-
ondary antibody (Molecular Probes). Hoechst (Sigma) was used to visualize
DNA. At least 300 cells were scored for each experiment, and experiments were
carried out with three to seven different batches of MEFs. When scoring cells for
centrosome numbers, binucleate cells were excluded from the analysis. It was not
possible to accurately determine the number of centrosomes in P7 MEFs as
80% of the cells contained no centrosomes (had been dispersed or degraded).
Statistics. For most comparisons, the Student t test (unpaired) was used to
generate a P value. For the Kaplan-Meier curves, the log rank test was used.
RESULTS
Generation of Rassf1A null and conditional mice. To assess
the physiologic role of RASSF1A, we used gene targeting to
generate mice lacking Rassf1A. In contrast to a previous study
in which Rassf1 and hence all the isoforms were deleted (16)
we specifically ablated the Rassf1A isoform by targeted dele-
tion of exon 1 (Fig. 1A). Furthermore, we used a conditional
approach to target Rassf1A, whereby the targeted locus con-
tained loxP sites flanking exon 1 and FRT sites flanking the
selection cassette (Fig. 1A). The conditional targeting vector
was introduced into ES cells and correctly targeted clones,
Rassf1A/Brdm1 (/m1), were identified by Southern blotting
(Fig. 1A). /m1 ES cell clones were then exposed to either
Flpe (to delete the selection cassette) or Cre (to delete both
exon 1 and the selection cassette) to generate the ES cell lines
with the Rassf1A/Brdc1 (/c1) and Rassf1A/Brdm2 (/m2) al-
leles, respectively (Fig. 1A). These ES cell clones were used to
generate chimeric mice that transmitted the mutated allele
through the germ line. All offspring were genotyped by PCR
using the strategy shown in Fig. 1B, which can distinguish
between the five possible genotypes (/, /c1, c1/c1, /m2,
and m2/m2).
Rassf1A null and conditional mice are viable, healthy, and
fertile. Interbreeding of heterozygous (/c1 or /m2) mice
produced homozygote conditional (c1/c1) and null (m2/m2)
offspring at the expected Mendelian ratios. These mice were
indistinguishable from littermate controls in terms of growth,
development, and reproductive abilities. No histological differ-
ences could be seen between wild-type /, c1/c1, and m2/m2
mice in all tissues examined (heart, lung, spleen, brain, thymus,
kidney, stomach, intestine, pancreas, and testis; data not
shown). RT-PCR performed on m2/m2 lung cDNA confirmed
the absence of Rassf1A exon 1, while the other major isoform,
Rassf1C, remained unaffected (Fig. 1C), as confirmed by quan-
titative RT-PCR (Fig. 1D). RT-PCR on c1/c1 lung cDNA
showed that the conditional allele was spliced appropriately,
the loxP site in the intron following exon 1 did not interfere
with splicing from exon 1 to exon 2, and, given that m2/m2
mice showed no obvious abnormalities, the c1 allele was not
characterized further. However, conditional inactivation of
Rassf1A using the c1/c1 mice will make it possible to evaluate
the role of Rassf1A in specific tissues.
Lymphocyte development is normal in Rassf1A null mice.
Rassf1A has been hypothesized to function as a negative reg-
ulator of cell cycle progression and cell proliferation (32).
Given that tight cell cycle control is important for lymphocyte
proliferation, we investigated the lymphocytic composition of
thymuses and spleens from Rassf1A null mice. Loss of Rassf1A
did not grossly affect thymic or splenic weight at either 6 to 7
weeks of age or 7 months of age (data not shown). Analysis of
thymuses from Rassf1A null mice showed a thymocyte popu-
lation comprising mainly double-positive (CD4 CD8) T
cells, nearly identical to that of wild-type mice (Fig. 2A). Fur-
thermore, similar proportions of mature CD4 and CD8 T
cells were present in the spleens of wild-type and Rassf1A null
mice (Fig. 2B). FACS analysis also demonstrated that the
percentage of cells in the thymus and spleen that expressed
CD2 (T-cell lineage) or CD45R (B220) (B-cell lineage) anti-
gens, respectively, were unchanged in Rassf1A null mice (Fig.
2A). Thus, loss of Rassf1A gene function does not affect the
lymphocytic component of the immune system.
Rassf1A null MEFs have no gross cell cycle defects. Numer-
ous studies performed using overexpression and short interfer-
ing RNA-mediated knockdown of RASSF1A in vitro have
lies adjacent to Rassf1. Southern blot analysis of the Rassf1A alleles was performed using three probes: pAS3 and pAT1, which are 5 and 3 of
the targeted allele, respectively, and pR20, which is on the conditional allele. Restriction enzyme sites and fragment sizes are as indicated. H,
HindIII; K, KpnI; N, NdeI; S, SacII. B. PCR genotyping of tail genomic DNA, using a combination of two primer pairs (either RSF-5/RSF-3 or
RSF-C/RSF-3), can distinguish between all five genotypes (/, /c1, c1/c1, /m2, and m2/m2) based on the presence and size of the product(s),
which can be resolved on a 2% agarose gel. C. RT-PCR was performed to confirm deletion of the floxed exons in Rassf1A null mice. RT-PCR
performed on RNA extracted from / and c1/c1 mice shows a 330-bp product corresponding to Rassf1A exons 1, 1, and 2. In contrast,
no such product is seen in RNA from m2/m2 mice. RNA from /, c1/c1, and m2/m2 mice all show 220- and 372-bp products corresponding to
exons 2 and 3 and 3 and 4 of Rassf1C and Rassf1 (common to all isoforms), respectively. -actin was used as a positive control for cDNA
production. D. Quantitative RT-PCR was performed to confirm there was no difference in the level of mRNA expression of the Rassf1C isoform
between wild-type and Rassf1A null mice. Data are presented as mean relative levels of Rassf1C mRNA  SD (n  4).
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FIG. 2. Analysis of thymic and splenic lymphocytes in Rassf1A null and wild-type animals. A. Spleens and thymuses were taken from adult
animals and stained with CD4-PI/CD8-FITC, CD2-FITC, or CD45R-FITC. A minimum of 10,000 events were analyzed from each organ. Data
are presented as means  SD (n  7). B. Propidium iodide cell cycle analysis on thymic and splenic lymphocytes. A minimum of 10,000 events
were analyzed from each organ. Data are presented as means  SD (n  7).
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implicated RASSF1A in playing a role in regulating cell cycle
and mitotic progression (5, 25, 32, 33, 39). However, FACS
analysis of propidium iodide-stained Rassf1A null and wild-
type thymocytes, splenocytes, and MEFs did not show any
accumulation of cells in a particular phase of the cell cycle (Fig.
2B and data not shown). There was also no difference in the
growth curves of Rassf1A null and wild-type MEFs (Fig. 3A).
Consistent with this, confocal microscopy of asynchronous
Rassf1A null MEFs also showed no difference in the propor-
tion of G2/M phase cells identified by phosphorylated histone
H3 (4) (Fig. 3B) or in S phase cells identified by BrdU incor-
poration (Fig. 3C). Transient knockdown of Rassf1A has been
previously shown to decrease the time spent in mitosis, pre-
sumably by premature APC/C activation and faster progres-
sion toward anaphase (33). In Rassf1A null MEFs, cells in each
mitotic phase were scored and no significant difference was
found in the proportion of premetaphase to postmetaphase
cells (Fig. 3D). A slight increase in prometaphase cells was
detected in Rassf1A null MEFs, which may reflect difficulties in
spindle assembly in the absence of Rassf1A. Thus the absence
of Rassf1A does not result in overt misregulation of the cell
cycle or mitotic progression.
Rassf1A null MEFs show an increased sensitivity to micro-
tubule-depolymerizing agents. Protection of microtubules by
Rassf1 has been shown previously (5, 16, 39), and we demon-
strate here that at least a portion of this activity can be attrib-
uted to the Rassf1A isoform. Rassf1A null MEFs showed more
extensive depolymerization of the microtubule network at low
concentrations of nocodazole compared to wild-type MEFs
(32.2%  10.7% versus 10.5%  1.1% of cells depolymerized
at 0.5 M, respectively; Fig. 4). Microtubule fibers could still
be detected at 1 M nocodazole in wild-type cells but could
hardly be seen in Rassf1A null MEFs at this concentration.
Similar results were found with another microtubule-depoly-
merizing agent, colcemid (data not shown).
Rassf1A null mice show no evidence of genomic stability.
Transient knockdown of Rassf1A in foreskin fibroblasts has
been shown to cause mitotic abnormalities including multiple
centrosomes and lagging chromosomes that were postulated to
contribute to genomic instability (33). However, Rassf1A null
MEFs did not display lagging chromosomes (data not shown)
or show distinct aberrations in centrosome numbers (P1 to P3),
although at later passages (P5) a larger percentage of cells with
more than two centrosomes was noticed than in wild-type cells
FIG. 3. Analysis of the cell cycle and mitotic properties of wild-type and Rassf1A null MEFs. A. Growth curves of wild-type (/) and Rassf1A
null (m2/m2) MEFs. Cell counts were performed in triplicate at intervals of 24 h. Data represent means  SD of four independently collected
batches of MEFs. B. PH3 staining of wild-type and Rassf1A null MEFs to analyze the proportion of the population in G2/M phase. At least 300
cells were scored for each experiment, and the data are presented as means  SD (n  3). C. BrdU staining of wild-type and Rassf1A null MEFs
to analyze the proportion of the population in S phase. At least 300 cells were scored for each experiment, and the data are presented as means
 SD (n  3). D. Analysis of the proportion of wild-type and Rassf1A null MEFs in each stage of mitosis. At least 200 cells were scored for each
experiment, and the data are presented as means  SD (n  3).
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(though not significant by Student’s t test analysis; Fig. 5A). A
complete analysis of the total chromosome content using spec-
tral karyotyping (SKY) of metaphase spreads from wild-type
and Rassf1A null MEFs showed no evidence of gross chromo-
somal rearrangements or aneuploidy (Fig. 5B). To confirm the
absence of aneuploidy in Rassf1A null MEFs, we used the
highly sensitive flow-cytometric micronucleus assay, which pro-
vides a quantitative measure of in vivo chromosome damage
(10). Micronuclei can arise from acentric chromosome frag-
ments or whole chromosomes that have not been incorporated
in the main nuclei at cell division (20). As shown in Fig. 5C,
Rassf1A null mice at either 6 to 7 weeks (0.24%  0.08%, n 
7) or 7 months of age (0.30%  0.08%, n  4) did not show
higher levels of micronuclei than wild-type littermates (0.27%
 0.06%, n 7 and 0.31% 0.06%, n 6, respectively). Since
irradiation can stimulate micronucleus formation (1, 30),
Rassf1A null mice at 6 to 7 weeks of age were irradiated with
0.7 Gy and blood was collected 48 h later. Still, irradiated
Rassf1A null mice (2.5%  0.8%, n  7) did not show signif-
icantly higher levels of micronuclei than irradiated wild-type
littermates (2.0%  0.9%, n  7; Fig. 5C). Taken together,
these data suggest that the absence of Rassf1A does not result
in gross genomic instability.
Rassf1A deficiency does not affect sensitivity to DNA-dam-
aging or microtubule-binding agents. To examine the effect of
Rassf1A deficiency on cell growth and viability after DNA
damage, we performed an MTT assay on Rassf1A null MEFs
exposed to a variety of DNA-damaging agents, including irra-
diation to induce DNA double-strand breaks, UV to induce
nucleotide alterations, and HU to inhibit DNA synthesis, as
well as the DNA cross-linking agent MMC and the alkylating
agent MMS. As shown in Fig. 6, Rassf1A null MEFs did not
show increased sensitivity compared to wild-type MEFs to the
induced forms of DNA damage or microtubule poisons. This
phenotype was confirmed in another cell type, by performing
clonogenic assays on double-targeted (m2/m2) ES cells (data
not shown). Thus Rassf1A deficiency does not impair check-
point responses triggered by DNA damage or failure to cor-
rectly assemble mitotic spindles.
Rassf1A deficiency plays a role in tumorigenesis. Using our
Rassf1A null mice, we addressed the key question of whether
loss of Rassf1A is relevant in tumorigenesis. As shown in Fig.
FIG. 4. Rassf1A null MEFs are more sensitive than wild-type MEFs to nocodazole-induced microtubule depolymerization. Wild-type and
Rassf1A null (m2/m2) MEFs were incubated with nocodazole at the indicated concentrations for 30 min before staining with anti--tubulin
antibody. At total of 100 to 150 cells were scored for each experiment, and the data are presented as means  standard errors of the means (n
 4), with representative images shown for each concentration. Asterisk, P  0.05 for / versus m2/m2 at the concentration indicated.
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7A, Rassf1A null mice showed a significantly reduced rate of
survival compared to wild-type littermates. In comparison to
the death of 30% of the wild-type mice, 50% of the Rassf1A
null mice died during the course of the study. In both cohorts
the predominant cause of death was cancer, in particular lym-
phoma (Table 1). In addition to the deaths shown in Table 1,
two Rassf1A null mice showed no tumors at the time of death
(both died from cardiac failure and pneumonia). To accelerate
tumorigenesis, Rassf1A null mice were irradiated with 3.5 Gy at
4 weeks of age (Fig. 7B). Irradiated Rassf1A null mice showed
an increased incidence of tumorigenesis and decreased survival
rate compared with wild-type mice, with 27 of the 39 Rassf1A
null mice dying (69%) compared to 24 of the 46 wild-type mice
(52%). It is noteworthy that, although the majority of all tu-
mors that developed were lymphomas, often with metastatic
spread to many organs, Rassf1A null mice showed more tumor
formation (adenomas and adenocarcinoma) in the gastrointes-
tinal (GI) tract than wild-type mice (Fig. 7C).
DISCUSSION
RASSF1A methylation has been reported in almost all types
of human cancer (reviewed in references 7 and 22). However,
how RASSF1A functions as a tumor suppressor gene remains
largely unknown. Recent work has suggested that RASSF1A
might provide the crucial link between tumor suppression and
the cell cycle (16, 33) by controlling the stability of microtu-
bules and the activity of APC/C. To delineate the role of
RASSF1A in the cell cycle and tumorigenesis, we have used a
genetic approach and generated Rassf1A knockout mice. Due
FIG. 5. Rassf1A null MEFS do not show evidence of increased genomic instability. A. Quantitation of centrosome numbers determined by
-tubulin staining of wild-type and Rassf1A null (m2/m2) MEFs at P1, P3, and P5. At least 300 cells were scored for each experiment, and the data
are presented as means  SD (n  7). B. SKY analysis. A SKY hybridization and detection kit was used to visualize the 19 autosomal and 2 sex
chromosomes in colors. At least 20 raw spectral image files were acquired for each genotype, and images were analyzed using SkyView software.
C. Micronucleus assays on blood from Rassf1A null and wild-type mice at 6 to 7 weeks of age (top), 6 to 7 weeks of age 48 h after irradiation with
0.7 Gy (center), and 7 months of age (bottom). Peripheral blood was stained with anti-CD71-FITC antibody and propidium iodide and analyzed
by flow cytometry. A minimum of 50,000 events were analyzed for each sample. Data represent analysis of blood from four to seven animals of
each genotype.
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to concerns that the homozygous null mice may be embryon-
ically lethal, we also generated a conditional Rassf1A allele.
However, Rassf1A null mice unexpectedly proved to be viable,
fertile, and healthy. Most surprisingly, loss of Rassf1A did not
grossly impair cell cycle progression in vivo. Lymphocytes from
Rassf1A null mice were identical to those from wild-type lit-
termates in terms of proportions of T and B lymphocytes and
showed no difference in the proportion of cells in each cell
cycle phase. The growth kinetics and cell cycle profiles of
Rassf1A null MEFs were indistinguishable from wild-type
MEFs. A closer, but stationary, analysis of the mitotic phases
revealed a subtle difference between Rassf1A null and wild-
type MEFs in the prometaphase population, the stage during
which spindle assembly occurs. Protection of microtubules by
Rassf1 has been shown previously (5, 39), and we demonstrate
that at least a portion of this activity can be attributed to the
Rassf1A isoform. This is consistent with the recent finding that
RASSF1C can bind tubulin but is far less effective than
RASSF1A at stabilizing microtubules (39).
The viability of the Rassf1A null mouse and the absence of
any obvious cell cycle defects are perhaps not altogether that
surprising, as the traditional view of the mammalian cell cycle
depicts many components as fulfilling essential steps that dic-
tate the sequential order of cell cycle events, yet Cyclin E,
Cyclin D, Cdk2, Cdk4, and Cdc25C knockout mice have all
been shown to be viable (reviewed in reference 34). Reasons
for this could include compensation by other proteins with
similar activity or the fact that some of these gene products
have major roles but only in specific cell lineages. Other rea-
sons could lie in the fact that most of the studies that declare
genes to be essential for regulation of the cell cycle stem from
analysis of cultured cells, many of which have defects in other
key regulatory genes. This is particularly relevant for
RASSF1A, as studies on the role of RASSF1A in the cell cycle
have largely been performed using transformed immortalized
cells such as HeLa cells, which have an abrogated Rb check-
point due to human papillomavirus E7 expression, or H1299
cells, which are p53 null. Therefore, these cells lack many of
the normal growth control regulations that would be imposed
on a cell in vivo.
Previous in vitro observations using RASSF1A mutant
cDNAs or transient knockdown of RASSF1A have led to the
hypothesis that an absence of RASSF1A results in genomic
instability (16, 33, 39). However, Rassf1A null mice did not
display increased genomic instability or abrogation of DNA
repair pathways. This lack of susceptibility to aneuploidy is
FIG. 6. Rassf1A null MEFs cells do not show an enhanced cytotoxicity to DNA damaging- and microtubule-binding agents. The cytoxicity of
DNA-damaging and microtubule-binding agents on Rassf1A null MEFs was examined using the MTT assay in a 96-well format (as described in
Materials and Methods). Treatments include the DNA-damaging agents irradiation, UV, MMS, MMC, and HU (A) and the microtubule-binding
agents nocodazole, colchicine, vinblastine, and taxol (B). Data were normalized to untreated cells of the same genotype, and results are expressed
as % survival (representing the means of four to six independent experiments  standard errors of the means).
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unlikely to be due to functional compensation by Rassf1C, as
Rassf1 null MEFs have also been reported to show no gross
chromosomal aberrations (16). A more likely explanation is
that, in order for a cell with such severe chromosomal abnor-
malities to be able to exist, defects in other key checkpoint
(tumor suppressor) genes would also need to be present.
We addressed the key question of whether loss of Rassf1A is
relevant in tumorigenesis. Rassf1A null mice showed a signif-
icantly increased incidence of tumorigenesis compared to wild-
type littermates. Irradiated Rassf1A null mice also showed a
reduced rate of survival and increased incidence of tumorigen-
esis, compared to irradiated wild-type mice. Irradiated het-
erozygous Rassf1A mice (/m2) did not show an increased
incidence of tumorigenesis or decreased rate of survival com-
pared to wild-type mice; however, given the small size of this
cohort (3 of the 12 mice [25%] developed tumors) the possi-
bility of a haploinsufficiency effect cannot be excluded. In both
the irradiated and nonirradiated cohorts, although the pre-
dominant tumor type was lymphoma, Rassf1A null mice
showed additional tumors associated with the gastrointestinal
tract, not commonly seen in the wild-type mice. Well-differen-
tiated endocrine carcinomas of gastric origin have been shown
to have frequent alterations in 3p21 (23), and epigenetic tran-
scriptional silencing of RASSF1A is a frequent event in gastric
tumorigenesis and might play an important role in the malig-
nant progression of gastric adenocarcinomas (3, 12, 35). In
addition, RASSF1A methylation has also been reported in
colorectal cancer and hepatocellular carcinomas (13, 26, 28, 37,
40, 44). Interestingly, these are the same tumor types in which
promoter methylation of the APC gene (adenomatous polyp-
osis coli [APC]) has also been reported (13). Given that APC
stimulates microtubule assembly and bundling (19, 45) and
that lack of microtubule binding associated with cancer-asso-
ciated mutations of APC are believed to contribute to defects
in the assembly of mitotic spindles and lead to missegregation
of chromosomes (8), it is tempting to speculate that aberrant
APC function may play a role in the neoplastic progression of
gastrointestional tract tissues with methylated or inactivated
RASSF1A.
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